Baricitinib
The spectrum of systemic treatment options in AE has recently expanded by approval of baricitinib, an oral JAK inhibitor. The small molecule has been proved efficacy and safety in several RCTs with an improvement of itch, patient-oriented eczema measure and DLQI [127].